Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 13.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 504,670 shares of the company’s stock after buying an additional 58,518 shares during the quarter. Dimensional Fund Advisors LP owned about 0.79% of Inozyme Pharma worth $1,398,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INZY. Barclays PLC raised its holdings in shares of Inozyme Pharma by 261.4% in the 3rd quarter. Barclays PLC now owns 76,730 shares of the company’s stock valued at $401,000 after buying an additional 55,497 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Inozyme Pharma by 31.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock worth $151,000 after acquiring an additional 6,851 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inozyme Pharma during the 4th quarter worth about $38,000. abrdn plc acquired a new position in shares of Inozyme Pharma during the 4th quarter worth about $472,000. Finally, Palumbo Wealth Management LLC lifted its holdings in shares of Inozyme Pharma by 52.3% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock valued at $64,000 after purchasing an additional 7,995 shares during the last quarter. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on INZY shares. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a report on Thursday, April 10th. Raymond James dropped their price objective on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective (down from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Piper Sandler dropped their price target on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. Finally, Needham & Company LLC dropped their price target on Inozyme Pharma from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $14.25.

Inozyme Pharma Price Performance

Shares of NASDAQ:INZY opened at $1.42 on Friday. Inozyme Pharma, Inc. has a 52 week low of $0.72 and a 52 week high of $6.24. The company has a market cap of $91.68 million, a P/E ratio of -0.91 and a beta of 1.35. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $1.03 and a 200-day simple moving average of $1.90.

Inozyme Pharma (NASDAQ:INZY) last issued its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). Equities research analysts forecast that Inozyme Pharma, Inc. will post -1.59 EPS for the current year.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.